A Phase I/IIa Study of AZD8205 Given Alone or Combined, in Participants With Advanced/Metastatic Solid Malignancies

Study Summary

This research study is studying a new compound, AZD8205, as a possible treatment for advanced or metastatic solid tumours alone or in combination with anti-cancer agents

Conditions

Breast Cancer Biliary Tract Carcinoma Ovarian Cancer Endometrial Cancer Squamous Non-Small Cell Lung Cancer

Interventions / Drugs

AZD8205 AZD8205 and AZD2936 (Rilvegostomig)AZD8205 and AZD5305 (saruparib)AZD8205 and AZD5305 (saruparib) and AZD2936 (rilvegostomig)AZD8205 in combination with AZD9574 AZD8205 in combination with AZD9574 plus rilvegostomig (AZD2936)

View on ClinicalTrials.gov ↗

Sponsor

Study Details

Enrollment460 participants

Primary Completion—

Lead SponsorAstraZeneca

Data Retrieved2026-04-11 02:55:19.911261+00:00

Not financial advice. BiotechSigns data is sourced from ClinicalTrials.gov, SEC EDGAR, and other public databases for research and informational purposes only. It does not constitute investment recommendations. Always do your own due diligence before making investment decisions.